MCID: UTR024
MIFTS: 59

Uterine Carcinosarcoma

Categories: Rare diseases, Reproductive diseases, Cancer diseases

Aliases & Classifications for Uterine Carcinosarcoma

MalaCards integrated aliases for Uterine Carcinosarcoma:

Name: Uterine Carcinosarcoma 12 53 59 55 6 15 73
Malignant Mixed Müllerian Tumor of the Corpus Uteri 53 59
Mixed Müllerian Cancer of Corpus Uteri 53 59
Carcinosarcoma of the Corpus Uteri 53 59
Malignant Mixed Müllerian Tumor of Corpus Uteri 53
Mixed Mullerian Sarcoma of Uterus 12
Uterine Corpus Carcinosarcoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:6171
NCIt 50 C42700
SNOMED-CT 68 702369008
Orphanet 59 ORPHA213610
ICD10 via Orphanet 34 C54.9

Summaries for Uterine Carcinosarcoma

Disease Ontology : 12 A uterine body mixed cancer that has material basis in both endometrial carcinoma and sarcoma.

MalaCards based summary : Uterine Carcinosarcoma, also known as malignant mixed müllerian tumor of the corpus uteri, is related to leiomyosarcoma and fallopian tube carcinoma, and has symptoms including pelvic pain An important gene associated with Uterine Carcinosarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include uterus, liver and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Uterine Carcinosarcoma

Diseases related to Uterine Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 leiomyosarcoma 31.1 KIT PGR TP53
2 fallopian tube carcinoma 30.9 ERBB2 PGR TP53
3 sarcoma 30.7 HRAS KIT PIK3CA TP53
4 endometrial stromal sarcoma 30.3 KIT MME PGR TP53
5 wilms tumor 1 30.2 CTNNB1 ERBB2 FBXW7 PGR TP53
6 adenosarcoma 30.0 KIT MME PGR TP53
7 chordoma 29.7 CDH1 EGFR PTEN TP53
8 cervical cancer 29.4 CTNNB1 ERBB2 HRAS PIK3CA PTEN PTGS2
9 adenocarcinoma 26.8 CDH1 CTNNB1 EGFR ERBB2 FGFR2 HRAS
10 colorectal cancer 26.4 CDH1 CTNNB1 EGFR ERBB2 ESR2 HRAS
11 endometrial cancer 25.0 CDH1 CTNNB1 EGFR ERBB2 ESR2 FGFR2
12 breast cancer 24.6 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
13 thyroid hurthle cell adenoma 11.0 PIK3CA PTEN
14 rare adenocarcinoma of the breast 11.0 PIK3CA TP53
15 endometrium carcinoma in situ 11.0 PGR TP53
16 thymoma, familial 11.0 HRAS KIT
17 breast duct papilloma 11.0 PGR PTEN
18 scirrhous adenocarcinoma 11.0 ERBB2 PGR
19 breast apocrine carcinoma 11.0 ERBB2 PGR
20 vestibular gland benign neoplasm 11.0 PGR TP53
21 bartholin's gland adenoma 11.0 PGR TP53
22 gallbladder squamous cell carcinoma 11.0 ERBB2 TP53
23 gastric papillary adenocarcinoma 11.0 ERBB2 TP53
24 esophagus adenocarcinoma 10.9 ERBB2 PIK3CA TP53
25 glassy cell carcinoma of the cervix 10.9 ERBB2 PGR
26 epithelial-myoepithelial carcinoma 10.9 FBXW7 HRAS TP53
27 breast mucoepidermoid carcinoma 10.9 ERBB2 PGR
28 adult hepatocellular carcinoma 10.9 CTNNB1 PIK3CA TP53
29 ovary adenocarcinoma 10.9 ERBB2 HRAS TP53
30 apocrine adenoma 10.9 HRAS PIK3CA
31 breast intraductal proliferative lesion 10.9 EGFR ERBB2
32 brain ependymoma 10.9 EGFR TP53
33 synchronous bilateral breast carcinoma 10.9 PGR PTEN TP53
34 aggressive digital papillary adenocarcinoma 10.8 HRAS KIT PIK3CA
35 ovarian melanoma 10.8 HRAS KIT PTEN
36 immunodeficiency 14 10.8 PIK3R1 PTEN
37 sweat gland cancer 10.8 ERBB2 PGR TP53
38 prostate transitional cell carcinoma 10.8 CTNNB1 PIK3CA
39 bladder adenocarcinoma 10.8 CTNNB1 FBXW7 HRAS
40 breast metaplastic carcinoma 10.8 ERBB2 PGR
41 melanoma, cutaneous malignant 1 10.8 HRAS PTEN TP53
42 female breast cancer 10.8 ERBB2 PGR TP53
43 ovarian clear cell carcinoma 10.8 PIK3CA PPP2R1A PTEN TP53
44 skin squamous cell carcinoma 10.7 FBXW7 HRAS PIK3CA TP53
45 embryonal sarcoma 10.7 CTNNB1 KIT TP53
46 gliomatosis cerebri 10.7 EGFR PTEN TP53
47 brain stem glioma 10.7 EGFR PIK3CA TP53
48 prostate squamous cell carcinoma 10.7 HRAS PIK3CA PPP2R1A TP53
49 barrett's adenocarcinoma 10.7 ERBB2 PTGS2 TP53
50 peutz-jeghers syndrome 10.7 CTNNB1 PTEN TP53

Graphical network of the top 20 diseases related to Uterine Carcinosarcoma:



Diseases related to Uterine Carcinosarcoma

Symptoms & Phenotypes for Uterine Carcinosarcoma

UMLS symptoms related to Uterine Carcinosarcoma:


pelvic pain

GenomeRNAi Phenotypes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.68 PIK3CA EGFR HRAS
2 Decreased viability GR00173-A 10.68 PIK3R2
3 Decreased viability GR00221-A-1 10.68 CDH1 KIT PIK3R2 PIK3CA PIK3R1 EGFR
4 Decreased viability GR00221-A-2 10.68 PIK3R2 PIK3CA HRAS
5 Decreased viability GR00221-A-3 10.68 PIK3R1 HRAS
6 Decreased viability GR00221-A-4 10.68 PIK3R2 PIK3CA EGFR
7 Decreased viability GR00301-A 10.68 CDH1 FGFR2 KIT PIK3R2
8 Decreased viability GR00342-S-1 10.68 FGFR2
9 Decreased viability GR00342-S-2 10.68 FGFR2
10 Decreased viability GR00342-S-3 10.68 FGFR2
11 Decreased viability GR00402-S-2 10.68 CDH1 FGFR2 KIT PIK3R2 PIK3CA PIK3R1
12 Decreased viability in esophageal squamous lineage GR00235-A 9.96 CDH1 CTNNB1 ERBB2 HRAS KIT PGR
13 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.91 CTNNB1 EGFR ERBB2 FGFR2 HRAS PPP2R1A
14 Decreased cell migration GR00055-A-1 9.8 HRAS PIK3CA PIK3R2 CTNNB1 EGFR
15 Increased transferrin (TF) endocytosis GR00363-A 9.8 SNAI2 SOX4 MME PIK3CA PIK3R1 PIK3R2
16 Increased cell death HMECs cells GR00103-A-0 9.76 CTNNB1 EGFR FBXW7 PGR PIK3CA PPP2R1A
17 Reduced mammosphere formation GR00396-S 9.17 CDH1 EGFR HRAS PIK3R1 PPP2R1A PTEN

MGI Mouse Phenotypes related to Uterine Carcinosarcoma:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.58 SOX4 TP53 CDH1 CTNNB1 EGFR ERBB2
2 homeostasis/metabolism MP:0005376 10.57 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
3 growth/size/body region MP:0005378 10.55 TP53 CDH1 CTNNB1 EGFR ERBB2 ESR2
4 cellular MP:0005384 10.5 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
5 endocrine/exocrine gland MP:0005379 10.5 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
6 behavior/neurological MP:0005386 10.48 CTNNB1 ERBB2 ESR2 FGFR2 HRAS KIT
7 integument MP:0010771 10.48 FBXW7 FGFR2 HRAS KIT MME PGR
8 digestive/alimentary MP:0005381 10.46 ERBB2 ESR2 FBXW7 FGFR2 HRAS CDH1
9 immune system MP:0005387 10.46 CDH1 CTNNB1 EGFR ESR2 FBXW7 FGFR2
10 mortality/aging MP:0010768 10.46 CTNNB1 EGFR ERBB2 ESR2 CDH1 FBXW7
11 embryo MP:0005380 10.45 CDH1 CTNNB1 EGFR ERBB2 FBXW7 FGFR2
12 neoplasm MP:0002006 10.41 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
13 hematopoietic system MP:0005397 10.39 TP53 CTNNB1 EGFR ESR2 FBXW7 FGFR2
14 craniofacial MP:0005382 10.32 CTNNB1 EGFR ERBB2 FBXW7 FGFR2 HRAS
15 muscle MP:0005369 10.31 CTNNB1 EGFR ERBB2 ESR2 FGFR2 KIT
16 normal MP:0002873 10.31 FGFR2 HRAS KIT PGR PIK3R1 PPP2R1A
17 nervous system MP:0003631 10.3 FGFR2 HRAS KIT CTNNB1 EGFR ERBB2
18 liver/biliary system MP:0005370 10.26 CTNNB1 EGFR ESR2 FBXW7 FGFR2 KIT
19 adipose tissue MP:0005375 10.24 EGFR ESR2 FGFR2 PIK3CA PIK3R1 PTEN
20 limbs/digits/tail MP:0005371 10.24 PTEN SOX4 TP53 ESR2 FGFR2 KIT
21 no phenotypic analysis MP:0003012 10.17 CTNNB1 EGFR ESR2 FGFR2 HRAS KIT
22 reproductive system MP:0005389 10.07 CDH1 CTNNB1 EGFR ERBB2 ESR2 FGFR2
23 hearing/vestibular/ear MP:0005377 10.06 CTNNB1 EGFR ESR2 FGFR2 KIT TP53
24 renal/urinary system MP:0005367 10.02 CTNNB1 EGFR ESR2 FGFR2 HRAS KIT
25 respiratory system MP:0005388 9.93 PTGS2 SOX4 TP53 CTNNB1 EGFR ERBB2
26 pigmentation MP:0001186 9.91 CTNNB1 EGFR FGFR2 KIT PTEN SNAI2
27 skeleton MP:0005390 9.8 SNAI2 SOX4 TP53 CTNNB1 EGFR ERBB2
28 vision/eye MP:0005391 9.36 CTNNB1 EGFR FBXW7 FGFR2 KIT PIK3CA

Drugs & Therapeutics for Uterine Carcinosarcoma

Drugs for Uterine Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
5
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
6
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
7
Ifosfamide Approved Phase 3 3778-73-2 3690
8
Mesna Approved, Investigational Phase 3 3375-50-6 598
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
11
Doxil Approved June 1999 Phase 3,Phase 2 31703
12 Alkylating Agents Phase 3,Phase 2
13 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
14 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
15 Antineoplastic Agents, Alkylating Phase 3,Phase 2
16 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
17
Isophosphamide mustard Phase 3 0
18 Topoisomerase Inhibitors Phase 3,Phase 2
19 Anti-Bacterial Agents Phase 3,Phase 2
20 Antibiotics, Antitubercular Phase 3,Phase 2
21
Histamine Phosphate Phase 3 51-74-1 65513
22 Serotonin Agents Phase 3
23 Serotonin Antagonists Phase 3
24 Gastrointestinal Agents Phase 3
25 Neurotransmitter Agents Phase 3
26 Histamine Antagonists Phase 3
27 Histamine H1 Antagonists Phase 3
28 Dermatologic Agents Phase 3
29 Anti-Allergic Agents Phase 3
30 Antipruritics Phase 3
31
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
32
Gemcitabine Approved Phase 2 95058-81-4 60750
33
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
34
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
35
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
36
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
37
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
38
Everolimus Approved Phase 2 159351-69-6 6442177
39
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
40
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
41
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
42
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
43
Metformin Approved Phase 2 657-24-9 14219 4091
44
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
45
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
46
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
47
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
49
Saracatinib Investigational Phase 2 379231-04-6
50
Iniparib Investigational Phase 2 160003-66-7

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
2 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
3 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
4 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
5 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
6 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
7 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
9 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
10 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
11 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
12 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
13 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
14 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
15 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
16 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
17 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
18 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
19 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
20 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
21 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
22 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
23 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
24 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
25 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
26 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
27 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
28 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
29 Vorinostat (SAHA) in Uterine Sarcoma Recruiting NCT03509207 Phase 2 Vorinostat Oral Capsule
30 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
31 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
32 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
33 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
34 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
35 Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus Terminated NCT00003156 Phase 2 topotecan hydrochloride
36 Suitability of DCE-MRI for Detection of Vascular Changes After VBT Unknown status NCT01991808 Phase 1
37 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Recruiting NCT03206177 Phase 1 Galunisertib;Paclitaxel;Carboplatin
38 Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Not yet recruiting NCT03552471 Phase 1 Rucaparib Camsylate
39 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
40 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer Unknown status NCT01367301 Not Applicable paclitaxel;carboplatin
41 Lymph Node Counts in Endometrial Cancer Staging Completed NCT02335775

Search NIH Clinical Center for Uterine Carcinosarcoma

Genetic Tests for Uterine Carcinosarcoma

Anatomical Context for Uterine Carcinosarcoma

MalaCards organs/tissues related to Uterine Carcinosarcoma:

41
Uterus, Liver, Lymph Node, Endothelial, Ovary, Lung

Publications for Uterine Carcinosarcoma

Articles related to Uterine Carcinosarcoma:

(show top 50) (show all 192)
# Title Authors Year
1
Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. ( 29791913 )
2018
2
Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. ( 29971677 )
2018
3
Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Evaluation of an Interesting Case of Uterine Carcinosarcoma with Isolated Appendicular Skeletal Metastases. ( 29643680 )
2018
4
Trends of uterine carcinosarcoma in the United States. ( 29400015 )
2018
5
Tumor Mutational Burden Guides Therapy in a Treatment Refractory<i>POLE-</i>Mutant Uterine Carcinosarcoma. ( 29386312 )
2018
6
The Association of an Elevated Thrombocyte Count with Clinicopathological Prognostic Factors and Survival in Patients with Uterine Carcinosarcoma. ( 29629727 )
2018
7
The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. ( 28940304 )
2018
8
Diagnostic accuracy of 3.0T diffusion-weighted MRI for patients with uterine carcinosarcoma: Assessment of tumor extent and lymphatic metastasis. ( 29437265 )
2018
9
Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. ( 29455465 )
2018
10
Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients With Uterine Carcinosarcoma. ( 29303931 )
2018
11
Significance of venous thromboembolism in women with uterine carcinosarcoma. ( 29248197 )
2018
12
Impact of radiotherapy modalities on outcomes in the adjuvant management of uterine carcinosarcoma: A National Cancer Database analysis. ( 29097136 )
2018
13
Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. ( 29056442 )
2017
14
Identification of distinct molecular subtypes of uterine carcinosarcoma. ( 28178664 )
2017
15
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. ( 28317560 )
2017
16
Prognostic value of metabolic parameters determined by preoperative A^a8,F-FDG PET/CT in patients with uterine carcinosarcoma. ( 28541634 )
2017
17
Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. ( 28930812 )
2017
18
Port-Site Metastasis of Uterine Carcinosarcoma after Laparoscopy. ( 28960047 )
2017
19
Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma. ( 28836024 )
2017
20
Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report. ( 28424084 )
2017
21
Use of Adjuvant Chemotherapy, Radiation Therapy, or Combined Modality Therapy and the Impact on Survival for Uterine Carcinosarcoma Limited to the Pelvis. ( 28574930 )
2017
22
Integrated Molecular Characterization of Uterine Carcinosarcoma. ( 28292439 )
2017
23
Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. ( 29044542 )
2017
24
Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival. ( 28121642 )
2017
25
Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. ( 27931750 )
2017
26
Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. ( 28088687 )
2017
27
Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. ( 28657223 )
2017
28
Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma. ( 28704324 )
2017
29
Secondary uterine carcinosarcoma after concurrent chemoradiotherapy for cervical cancer: Case reports. ( 28761924 )
2017
30
Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database Analysis. ( 28654573 )
2017
31
Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma. ( 28193280 )
2017
32
A predictive diagnostic model using multiparametric MRI for differentiating uterine carcinosarcoma from carcinoma of the uterine corpus. ( 28584958 )
2017
33
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. ( 28318642 )
2017
34
Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. ( 28215838 )
2017
35
Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis. ( 27009459 )
2016
36
Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes. ( 26896827 )
2016
37
Uterine carcinosarcoma including angiosarcoma: A short case report. ( 27592347 )
2016
38
Unusual Cutaneous Metastasis of Uterine Carcinosarcoma: A Case Report and Review of the Literature. ( 26675357 )
2016
39
Comparison of MRI and (18)F-FDG PET/CT in the preoperative evaluation of uterine carcinosarcoma. ( 26777990 )
2016
40
Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. ( 27072806 )
2016
41
RNA-seq identification of RACGAP1 as a metastatic driver in uterine carcinosarcoma. ( 27121792 )
2016
42
Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Carcinosarcoma: A Retrospective Case Series. ( 26941453 )
2016
43
Expression of aurora kinases: Predictor of tumor dissemination in uterine carcinosarcoma. ( 27779297 )
2016
44
Utility of histogram analysis of apparent diffusion coefficient maps obtained using 3.0T MRI for distinguishing uterine carcinosarcoma from endometrial carcinoma. ( 26605502 )
2016
45
Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study. ( 27441069 )
2016
46
Prognostic impact of primary tumor SUVmax on preoperative (18)F-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography in endometrial cancer and uterine carcinosarcoma. ( 27703679 )
2016
47
Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08). ( 27550404 )
2016
48
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( 27172745 )
2016
49
Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS. ( 27889902 )
2016
50
Prognostic value of total lesion glycolysis on preoperative (18)F-FDG PET/CT in patients with uterine carcinosarcoma. ( 26883331 )
2016

Variations for Uterine Carcinosarcoma

ClinVar genetic disease variations for Uterine Carcinosarcoma:

6
(show top 50) (show all 342)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
5 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
6 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
7 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
8 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
9 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
10 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
11 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
12 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
13 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
14 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
20 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
21 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
22 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
23 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
24 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
25 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
26 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
27 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
28 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
29 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
30 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
31 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
32 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh38 Chromosome 10, 121520163: 121520163
33 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
34 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
35 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
36 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
37 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
38 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
39 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
40 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
41 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
42 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
43 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
44 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
45 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
46 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
47 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
48 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
49 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh38 Chromosome 3, 179234296: 179234296
50 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095

Expression for Uterine Carcinosarcoma

Search GEO for disease gene expression data for Uterine Carcinosarcoma.

Pathways for Uterine Carcinosarcoma

Pathways related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 186)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.33 CDH1 CTNNB1 EGFR ERBB2 FBXW7 FGFR2
2
Show member pathways
14.18 CDH1 CTNNB1 EGFR ERBB2 FBXW7 FGFR2
3
Show member pathways
14.01 EGFR ERBB2 FGFR2 HRAS KIT PIK3R1
4
Show member pathways
13.97 CDH1 CTNNB1 EGFR ERBB2 ESR2 FGFR2
5
Show member pathways
13.89 EGFR ERBB2 ESR2 FGFR2 HRAS KIT
6
Show member pathways
13.88 CDH1 CTNNB1 EGFR ERBB2 FBXW7 FGFR2
7
Show member pathways
13.84 EGFR ERBB2 FGFR2 HRAS KIT PIK3R1
8
Show member pathways
13.69 CTNNB1 EGFR ERBB2 FGFR2 HRAS KIT
9
Show member pathways
13.67 EGFR ERBB2 FGFR2 HRAS KIT PIK3R1
10
Show member pathways
13.67 CTNNB1 EGFR ERBB2 FGFR2 HRAS KIT
11
Show member pathways
13.6 CDH1 EGFR ERBB2 FBXW7 FGFR2 HRAS
12
Show member pathways
13.59 EGFR ERBB2 FGFR2 HRAS KIT PIK3R1
13
Show member pathways
13.54 EGFR ERBB2 FGFR2 HRAS KIT PIK3CA
14
Show member pathways
13.48 EGFR ERBB2 FGFR2 HRAS KIT PIK3R1
15
Show member pathways
13.47 CDH1 CTNNB1 EGFR ERBB2 FGFR2 HRAS
16
Show member pathways
13.45 CDH1 CTNNB1 EGFR ERBB2 ESR2 FGFR2
17
Show member pathways
13.31 EGFR ERBB2 FGFR2 KIT PIK3CA PIK3R1
18
Show member pathways
13.25 EGFR FGFR2 HRAS KIT PIK3R1 PIK3R2
19
Show member pathways
13.23 EGFR FGFR2 HRAS KIT PIK3R1 PIK3R2
20
Show member pathways
13.22 EGFR HRAS PIK3R1 PIK3R2 PPP2R1A PTGS2
21
Show member pathways
13.22 EGFR ESR2 HRAS PGR PIK3CA PIK3R1
22
Show member pathways
13.17 CTNNB1 EGFR HRAS PIK3R1 PIK3R2 PTGS2
23
Show member pathways
13.15 CDH1 CTNNB1 HRAS PIK3R1 PIK3R2 TP53
24
Show member pathways
13.1 EGFR HRAS KIT PIK3CA PIK3R1 PIK3R2
25
Show member pathways
13.1 CDH1 CTNNB1 HRAS PIK3R1 PIK3R2 PPP2R1A
26
Show member pathways
13.09 EGFR ERBB2 HRAS PIK3CA PIK3R1 PIK3R2
27
Show member pathways
13.09 CTNNB1 EGFR ERBB2 HRAS PIK3CA PIK3R1
28
Show member pathways
13.06 EGFR ERBB2 FGFR2 HRAS PIK3CA PIK3R1
29
Show member pathways
12.96 EGFR ERBB2 HRAS PIK3R1 PIK3R2 PTEN
30 12.94 EGFR ERBB2 FGFR2 HRAS KIT TP53
31
Show member pathways
12.93 HRAS PIK3CA PIK3R1 PIK3R2 TP53
32
Show member pathways
12.93 CTNNB1 HRAS PIK3R1 PIK3R2 PPP2R1A
33
Show member pathways
12.93 CDH1 CTNNB1 EGFR FGFR2 HRAS KIT
34
Show member pathways
12.9 CTNNB1 EGFR ERBB2 FGFR2 HRAS KIT
35
Show member pathways
12.87 CTNNB1 EGFR HRAS PIK3CA PIK3R1 PIK3R2
36
Show member pathways
12.85 EGFR HRAS PIK3R1 PIK3R2 PPP2R1A TP53
37
Show member pathways
12.85 CDH1 CTNNB1 ERBB2 HRAS PIK3CA PIK3R1
38
Show member pathways
12.84 CDH1 CTNNB1 PIK3CA PIK3R1 PIK3R2
39
Show member pathways
12.84 CDH1 CTNNB1 EGFR ERBB2 FGFR2 HRAS
40 12.81 EGFR FGFR2 HRAS PIK3CA PIK3R1 PIK3R2
41
Show member pathways
12.81 CDH1 EGFR ERBB2 ESR2 FGFR2 HRAS
42
Show member pathways
12.8 EGFR HRAS PIK3CA PIK3R1 PIK3R2
43
Show member pathways
12.79 CTNNB1 EGFR ERBB2 HRAS PIK3CA PIK3R1
44
Show member pathways
12.78 HRAS PIK3CA PIK3R1 PIK3R2 PTEN PTGS2
45
Show member pathways
12.78 CTNNB1 HRAS PIK3CA PIK3R1 PIK3R2 PTEN
46
Show member pathways
12.76 EGFR HRAS PIK3CA PIK3R1 PIK3R2 PPP2R1A
47
Show member pathways
12.75 EGFR ERBB2 FGFR2 HRAS KIT PIK3CA
48
Show member pathways
12.72 FGFR2 HRAS PIK3CA PIK3R1 PPP2R1A
49
Show member pathways
12.7 ERBB2 ESR2 HRAS PIK3CA PIK3R1 PIK3R2
50
Show member pathways
12.7 CDH1 CTNNB1 EGFR ERBB2 HRAS PIK3CA

GO Terms for Uterine Carcinosarcoma

Cellular components related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.67 EGFR ERBB2 FGFR2 KIT
2 lateral plasma membrane GO:0016328 9.58 CDH1 CTNNB1 PPP2R1A
3 cytoplasm GO:0005737 9.58 CDH1 CTNNB1 EGFR ERBB2 FBXW7 FGFR2
4 cytoplasmic side of plasma membrane GO:0009898 9.5 CDH1 KIT PTEN
5 flotillin complex GO:0016600 9.43 CDH1 CTNNB1
6 phosphatidylinositol 3-kinase complex, class IA GO:0005943 9.16 PIK3CA PIK3R1
7 phosphatidylinositol 3-kinase complex GO:0005942 9.13 PIK3CA PIK3R1 PIK3R2
8 nucleus GO:0005634 10.13 CTNNB1 EGFR ERBB2 ESR2 FBXW7 FGFR2

Biological processes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine phosphorylation GO:0018108 9.99 EGFR ERBB2 FGFR2 KIT
2 protein stabilization GO:0050821 9.99 FBXW7 PIK3R1 PTEN SOX4
3 negative regulation of signal transduction GO:0009968 9.95 EGFR ERBB2 FGFR2 KIT
4 positive regulation of DNA binding transcription factor activity GO:0051091 9.94 CTNNB1 ESR2 KIT PTEN
5 response to estradiol GO:0032355 9.93 CTNNB1 EGFR PTEN PTGS2
6 response to organic substance GO:0010033 9.92 CDH1 PPP2R1A PTEN PTGS2
7 canonical Wnt signaling pathway GO:0060070 9.91 CTNNB1 PTEN SNAI2 SOX4
8 negative regulation of apoptotic process GO:0043066 9.91 EGFR ERBB2 FGFR2 KIT PIK3R1 PTEN
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 EGFR PIK3CA PTGS2
10 signal transduction by protein phosphorylation GO:0023014 9.89 EGFR ERBB2 KIT
11 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.89 PIK3CA PIK3R1 PIK3R2
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 EGFR FGFR2 PTGS2
13 cellular response to growth factor stimulus GO:0071363 9.88 CTNNB1 EGFR ERBB2
14 phosphatidylinositol biosynthetic process GO:0006661 9.88 PIK3CA PIK3R1 PIK3R2 PTEN
15 cellular response to UV GO:0034644 9.87 PIK3R1 PTGS2 TP53
16 positive regulation of kinase activity GO:0033674 9.87 EGFR ERBB2 FGFR2 KIT
17 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.87 EGFR ERBB2 FBXW7 FGFR2 HRAS KIT
18 phosphatidylinositol-mediated signaling GO:0048015 9.85 PIK3CA PIK3R1 PIK3R2
19 cellular response to epidermal growth factor stimulus GO:0071364 9.85 EGFR ERBB2 SNAI2
20 positive regulation of MAPK cascade GO:0043410 9.85 CTNNB1 EGFR ERBB2 FGFR2 HRAS KIT
21 epithelial to mesenchymal transition GO:0001837 9.84 CTNNB1 FGFR2 SNAI2
22 positive regulation of MAP kinase activity GO:0043406 9.84 EGFR ERBB2 HRAS KIT
23 T cell differentiation GO:0030217 9.83 CTNNB1 KIT SOX4
24 response to radiation GO:0009314 9.83 KIT PTGS2 SNAI2
25 positive regulation of epithelial cell proliferation GO:0050679 9.83 EGFR ERBB2 FGFR2 HRAS
26 regulation of ERK1 and ERK2 cascade GO:0070372 9.81 EGFR ERBB2 FGFR2
27 epidermal growth factor receptor signaling pathway GO:0007173 9.81 EGFR HRAS PIK3CA PIK3R1
28 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.8 FGFR2 PIK3CA PIK3R1 PIK3R2
29 vasculature development GO:0001944 9.79 CTNNB1 FBXW7 PIK3CA
30 phosphatidylinositol 3-kinase signaling GO:0014065 9.76 ERBB2 PIK3CA PIK3R1 PIK3R2
31 tongue development GO:0043586 9.73 EGFR KIT
32 morphogenesis of embryonic epithelium GO:0016331 9.73 CTNNB1 FGFR2
33 entry of bacterium into host cell GO:0035635 9.73 CDH1 CTNNB1
34 obsolete positive regulation of transcription factor import into nucleus GO:0042993 9.73 CDH1 PIK3R1 PIK3R2
35 positive regulation of protein import into nucleus GO:0042307 9.73 CDH1 PIK3R1 PIK3R2 PTGS2
36 limb bud formation GO:0060174 9.72 FGFR2 SOX4
37 regulation of phosphatidylinositol 3-kinase activity GO:0043551 9.72 PIK3R1 PIK3R2
38 regulation of osteoblast differentiation GO:0045667 9.72 CTNNB1 FGFR2 SNAI2
39 lung-associated mesenchyme development GO:0060484 9.71 CTNNB1 FGFR2
40 cellular response to indole-3-methanol GO:0071681 9.68 CDH1 CTNNB1
41 mesenchymal cell proliferation involved in lung development GO:0060916 9.65 CTNNB1 FGFR2
42 ERBB2 signaling pathway GO:0038128 9.55 EGFR ERBB2 HRAS PIK3CA PIK3R1
43 positive regulation of protein kinase B signaling GO:0051897 9.5 EGFR ERBB2 FGFR2 KIT PIK3CA PIK3R1
44 phosphatidylinositol phosphorylation GO:0046854 9.17 EGFR ERBB2 FGFR2 KIT PIK3CA PIK3R1
45 signal transduction GO:0007165 10.36 CTNNB1 EGFR ERBB2 ESR2 HRAS KIT
46 multicellular organism development GO:0007275 10.26 CDH1 EGFR ERBB2 FGFR2 KIT SNAI2
47 protein phosphorylation GO:0006468 10.16 EGFR ERBB2 FGFR2 KIT PIK3CA PIK3R1
48 positive regulation of transcription, DNA-templated GO:0045893 10.15 CDH1 CTNNB1 EGFR ESR2 SOX4 TP53
49 positive regulation of transcription by RNA polymerase II GO:0045944 10.13 CTNNB1 EGFR FGFR2 HRAS PGR PIK3R1
50 negative regulation of cell proliferation GO:0008285 10.09 CTNNB1 HRAS PTEN PTGS2 SOX4 TP53

Molecular functions related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.96 EGFR ERBB2 FGFR2 HRAS KIT
2 protein tyrosine kinase activity GO:0004713 9.85 EGFR ERBB2 FGFR2 KIT
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.81 EGFR ERBB2 FGFR2 KIT
4 enzyme binding GO:0019899 9.8 CTNNB1 EGFR ESR2 PGR PTEN PTGS2
5 MAP kinase kinase kinase activity GO:0004709 9.78 EGFR ERBB2 FGFR2 KIT
6 mitogen-activated protein kinase kinase binding GO:0031434 9.76 EGFR ERBB2 FGFR2 KIT
7 protein heterodimerization activity GO:0046982 9.76 CTNNB1 EGFR ERBB2 PIK3R1 PIK3R2 PPP2R1A
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.73 EGFR ERBB2 FGFR2 KIT
9 core promoter sequence-specific DNA binding GO:0001046 9.71 ESR2 SOX4 TP53
10 1-phosphatidylinositol-3-kinase activity GO:0016303 9.67 FGFR2 PIK3CA PIK3R1 PIK3R2
11 insulin receptor substrate binding GO:0043560 9.58 PIK3CA PIK3R1
12 1-phosphatidylinositol-3-kinase regulator activity GO:0046935 9.58 PIK3R1 PIK3R2
13 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.58 EGFR ERBB2 KIT
14 phosphatidylinositol 3-kinase regulator activity GO:0035014 9.57 PIK3R1 PIK3R2
15 ErbB-3 class receptor binding GO:0043125 9.52 ERBB2 PIK3R1
16 protein phosphatase binding GO:0019903 9.43 CTNNB1 EGFR ERBB2 PIK3R1 PIK3R2 TP53
17 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.17 EGFR ERBB2 FGFR2 KIT PIK3CA PIK3R1
18 protein binding GO:0005515 10.32 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
19 identical protein binding GO:0042802 10.1 CDH1 EGFR ERBB2 ESR2 FBXW7 PGR

Sources for Uterine Carcinosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....